Department of Gynecologic Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
IHU-Strasbourg (Institut Hospitalo-Universitaire), Strasbourg, France.
J Invest Surg. 2022 Jun;35(6):1394-1401. doi: 10.1080/08941939.2022.2045396. Epub 2022 Mar 1.
To assess the laparoscopic interval debulking surgery (IDS) outcomes compared to laparotomy, by analyzing the overall survival (OS) and the progression free survival (PFS), as well as the intra- and post-operative morbidity. In this retrospective propensity-score-matched cohort study, all patients with stage III or IV FIGO (International Federation of Gynecology and Obstetrics) serous ovarian cancer, undergoing complete IDS after neoadjuvant chemotherapy, from January 1st of 2009 to June 1st 2019, were included. Thirty-seven patients were included in the laparoscopy group and 40 in the laparotomy group. There was no significant difference in terms of median OS between laparoscopy and laparotomy (23.1 months [95% CI 15.7-29.7] versus 26.3 months [95% CI 21.7-31.7], respectively, = 0.17) and median PFS (14.8 months [95% CI 10.6-21.5] versus 12 months [95% CI 11-15.1], = 0.057). After applying the propensity score, 25 patients were included in each group. Laparoscopy was associated with significantly less early postoperative complications (6 versus 17, = 0.01) and shorter hospital stay (7.6 days versus 12.1, < 0.001) and a significantly better OS (HR 0.45 [95% CI 0.19-0.95], = 0.04), but with no significant difference in terms of PFS (HR 0.71 [95% CI 0.27-1.88], = 0.49). In carefully-selected patients with advanced ovarian cancer, complete laparoscopic interval debulking surgery achieves similar survival outcomes to open laparotomy. Therefore, laparoscopy appears as a safe alternative to laparotomy for IDS after NACT in selected patients with advanced ovarian cancer and a low burden of disease.
为了评估与开腹手术相比,腹腔镜间隔减瘤术(IDS)的结果,通过分析总生存期(OS)和无进展生存期(PFS),以及围手术期发病率。在这项回顾性倾向评分匹配队列研究中,所有接受新辅助化疗后完全 IDS 的 III 期或 IV 期国际妇产科联合会(FIGO)浆液性卵巢癌患者均被纳入研究。从 2009 年 1 月 1 日至 2019 年 6 月 1 日,共有 37 例患者纳入腹腔镜组,40 例患者纳入开腹组。腹腔镜组和开腹组的中位 OS 无显著差异(分别为 23.1 个月[95%CI 15.7-29.7]和 26.3 个月[95%CI 21.7-31.7], = 0.17)和中位 PFS(14.8 个月[95%CI 10.6-21.5]和 12 个月[95%CI 11-15.1], = 0.057)。应用倾向评分后,每组纳入 25 例患者。腹腔镜手术与术后早期并发症显著减少(6 例与 17 例, = 0.01)和住院时间缩短(7.6 天与 12.1 天, < 0.001)和显著改善 OS(HR 0.45[95%CI 0.19-0.95], = 0.04)有关,但 PFS 无显著差异(HR 0.71[95%CI 0.27-1.88], = 0.49)。在精心挑选的晚期卵巢癌患者中,完全腹腔镜间隔减瘤术的生存结果与开腹手术相似。因此,对于晚期卵巢癌且疾病负担较低的患者,在新辅助化疗后,腹腔镜 IDS 似乎是开腹手术的一种安全替代方案。